Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB

Neither bebtelovimab nor any mAb combinations tested neutralized the SARS-CoV-2 omicron subvariants BQ.1.1 and XBB, but remdesivir, molnupiravir, and nirmatrelvir were efficacious against both in vitro.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-01, Vol.388 (1), p.89-91
Hauptverfasser:	Imai, Masaki, Ito, Mutsumi, Kiso, Maki, Yamayoshi, Seiya, Uraki, Ryuta, Fukushi, Shuetsu, Watanabe, Shinji, Suzuki, Tadaki, Maeda, Ken, Sakai-Tagawa, Yuko, Iwatsuki-Horimoto, Kiyoko, Halfmann, Peter J., Kawaoka, Yoshihiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Coronavirus Coronaviruses Correspondence COVID-19 COVID-19 - virology COVID-19 Drug Treatment Disease transmission Drugs FDA approval Humans Infectious Disease Infectious diseases Medical research Monoclonal antibodies R&D Research & development RNA polymerase SARS-CoV-2 - drug effects Severe acute respiratory syndrome coronavirus 2 Treatment Outcome Viral Infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Neither bebtelovimab nor any mAb combinations tested neutralized the SARS-CoV-2 omicron subvariants BQ.1.1 and XBB, but remdesivir, molnupiravir, and nirmatrelvir were efficacious against both in vitro.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2214302